Monitoring And Improving Hepatitis C Health Outcomes Among People With Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
In Australia, hepatitis C is associated with considerable morbidity and mortality, costing $9.2 billion to the health care system. In the next year, side-effect prone hepatitis C therapies will be replaced with simple, tolerable, interferon-free therapies (cure >90%) that can reverse liver disease progression. My goal is to further develop my established research program in population-health related to HCV epidemiology, and therapeutic strategies, with a specific focus on PWID.
Recently Acquired Hepatitis C Infection: Insights From Virological, Therapeutic And Epidemiological Studies
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Every year around 10,000 new cases of hepatitis C (HCV) infection occur within Australia, most of which are undiagnosed. Reasons for this include a lack of public awareness about the benefits of treatment at this stage. As new antiviral agents become available it is likely that therapy for recent HCV will become even easier and more successful. The aim of this research is to explore HCV transmission patterns, treatment strategies and long term health outcomes in people with recent HCV.
Epidemiology, Natural History And Treatment Of Hepatitis C Virus Infection In Injecting Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
In Australia, the majority of hepatitis C is acquired by injecting drug users (IDUs). Given the asymptomatic nature of infection and difficulties in identifying and following those at risk of acquiring infection, our knowledge of hepatitis C has been hampered. The overall goal of this proposed research is to assess markers to better diagnose and predict clearance of hepatitis C, assess hepatitis C transmission and assess health services to enhance HCV assessment and treatment among IDUs.
Dependent drug use is associated with a range of physical and mental health problems. However the process by which drug-related changes to the human brain influence behaviours important to remaining abstinent is poorly understood. The current proposal investigates the neural and behavioural effects of drug dependence on cognitive control - responsible for impulse control and decision making - previously implicated in drug dependence.
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.
Dissecting The Interactions Of Antimalarial Drugs With The Two Key Determinants Of Drug Resistance In The Malaria Parasite - The 'chloroquine Resistance Transporter' And The 'multidrug Resistance Transporter 1'
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The malaria parasite is a single-celled organism which invades the red blood cells of its host. The aim of this fellowship is to study two proteins that are central to the parasite’s ability to evade the toxic effects of a number of drugs. The parasite's susceptibility to chloroquine, and other drugs, is altered by small changes in these proteins. This work will advance our understanding of the increasingly widespread phenomenon of antimalarial drug resistance, and of how it may be overcome.
Determining The Bacterial Contributions To Tuberculosis And Identification Of Drug Targets
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Serious issues of drug resistance have emerged in tuberculosis prevention and are placing enormous pressure on global health systems. We have identified an enzyme of M. tuberculosis that is essential for its survival. This project will develop potent inhibitory compounds for this enzyme. Further, we will identify new drug targets through a screen to specifically identify the genes of the organism essential for its survival in the body. This information will be used to develop new TB drugs.
In this fellowship I will develop methods to improve the way drugs are delivered through the use of nanotechnology. Nanoparticles can be used to protect delicate drugs from degrading, and to make sure drugs are delivered where they are required. This helps to lower side effects and improve efficacy of a range of drugs. I lead a multi-disciplinary research team dedicated to understanding of how nanoparticles interact with biological systems, so we can engineer better drug delivery systems.